Abstract
This prospective, single-arm, open label pilot study evaluated the clinical efficacy of secukinumab therapy in adult onset pityriasis rubra pilaris (PRP). A total of 10 patients with PRP were included. Baseline characteristics, Dermatology Life Quality Index (DLQI) score, Psoriatic Area and Severity Index (PASI) score, Physician Global Assessment (PGA), and adverse events were collected. Reduction in PASI score by ≥75% of baseline value and by ≥90% of baseline value were calculated at week 12 and week 28.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
